Automating Ancillary Processes: Closing the New Bottleneck in Cell and Gene Therapy Manufacturing

Manual media formulation and viral vector packaging are time-intensive, tedious, and expensive activities. 

In this on-demand webinar, industry experts share challenges encountered when closing and automating ancillary processes, and how improved scalability and reproducibility were achieved by moving to closed automated platforms. 

Access the on-demand recording to hear about:

  • The challenges and benefits of moving media formulation and viral vector packaging from manual to automated systems
  • Reducing process variability and risk
  • Potential future changes that could simply large-scale media formulation and viral vector packaging
  • Economic considerations when evaluating trade-offs of moving to closing formulation and fill systems


David_Hodl _headshots_300x300pxDavid Hodl
Head of Business Development at Invetech

Amy_Shaw_300x300pxAmy Shaw
Lead, Cell Therapies Engineering and Automation Development at Takeda

Randy_Schweickart_300x300pxRandy Schweickart
Senior Director, Process Technology Development at Bristol Myers Squibb

Farid_Ighemat_300x300pxFarid Ighemat
Sr. Director, Manufacturing, Cell and Gene Therapy - R&D at GlaxoSmithKline

Access On-Demand Video Recording

Let’s create tomorrow’s cell and gene therapy solutions

Invetech helps cell and gene therapy developers to visualize, strategize and manage the future. With proven processes, expert insights and full-spectrum services, we swiftly accelerate vital, emerging therapies from the clinic to commercial-scale manufacturing. Together with our partners, we expand the reach of next-generation medical advances that are revolutionizing healthcare. Learn more at invetechgroup.com

Organovo logo-2
Humacyte logo-2